Undisclosed CSF-1R inhibitor / BCI Pharma, Mithra - LARVOL DELTA

Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program (GlobeNewswire) - "Mithra...today announces new positive data from preclinical studies on inhibitors of CSF-1R in development, in collaboration with BCI Pharma, for treatment of endometriosis, oncology and inflammatory disorders....Colony-stimulating factor 1 receptor (CSF-1R) is a cell-surface tyrosine kinase receptor and a key regulator of macrophage biology and homeostasis. Tumor-associated macrophages are key components of the tumor microenvironment and have emerged as a promising avenue for discovery of novel cancer immunotherapies. CSF-1R kinase inhibition is therefore a promising therapeutic strategy for cancer treatment."

Licensing / partnership • Preclinical • Oncology